UY32109A - Métodos para utilizar composiciones de liberación sostenida de aminopiridina - Google Patents

Métodos para utilizar composiciones de liberación sostenida de aminopiridina

Info

Publication number
UY32109A
UY32109A UY0001032109A UY32109A UY32109A UY 32109 A UY32109 A UY 32109A UY 0001032109 A UY0001032109 A UY 0001032109A UY 32109 A UY32109 A UY 32109A UY 32109 A UY32109 A UY 32109A
Authority
UY
Uruguay
Prior art keywords
sustained release
composition
aminopiridine
methods
release compositions
Prior art date
Application number
UY0001032109A
Other languages
English (en)
Spanish (es)
Inventor
Andrew R Blight
Cohen Ron
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32109(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of UY32109A publication Critical patent/UY32109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UY0001032109A 2008-09-10 2009-09-10 Métodos para utilizar composiciones de liberación sostenida de aminopiridina UY32109A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
UY32109A true UY32109A (es) 2010-04-30

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032109A UY32109A (es) 2008-09-10 2009-09-10 Métodos para utilizar composiciones de liberación sostenida de aminopiridina

Country Status (15)

Country Link
US (3) US20100061935A1 (ja)
EP (1) EP2343976A4 (ja)
JP (1) JP2012502103A (ja)
CN (1) CN101827522A (ja)
AR (1) AR073573A1 (ja)
AU (1) AU2009291781A1 (ja)
BR (1) BRPI0903914A2 (ja)
CA (1) CA2736381A1 (ja)
CL (1) CL2009001841A1 (ja)
PA (1) PA8841801A1 (ja)
PE (1) PE20100264A1 (ja)
RU (1) RU2011113762A (ja)
TW (1) TW201010703A (ja)
UY (1) UY32109A (ja)
WO (1) WO2010030755A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
CA2864340A1 (en) * 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (ja) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
CA2534711A1 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
AU2006292064A1 (en) * 2005-09-23 2007-03-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment

Also Published As

Publication number Publication date
AU2009291781A1 (en) 2010-03-18
CN101827522A (zh) 2010-09-08
US20130072527A1 (en) 2013-03-21
CL2009001841A1 (es) 2011-02-18
BRPI0903914A2 (pt) 2015-07-21
JP2012502103A (ja) 2012-01-26
EP2343976A1 (en) 2011-07-20
PA8841801A1 (es) 2010-06-28
PE20100264A1 (es) 2010-04-28
EP2343976A4 (en) 2011-12-14
WO2010030755A1 (en) 2010-03-18
US20100061935A1 (en) 2010-03-11
CA2736381A1 (en) 2010-03-18
US20130330277A1 (en) 2013-12-12
RU2011113762A (ru) 2012-10-20
AR073573A1 (es) 2010-11-17
TW201010703A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
UY32109A (es) Métodos para utilizar composiciones de liberación sostenida de aminopiridina
HRP20130424T1 (en) Methods of using sustained release aminopyridine compositions
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
AR062760A1 (es) Administracion de inhibidores de dipeptidilpetidasa
GB201018289D0 (en) Treatment of respiratory disorders
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
RS52120B (en) STERILE IMMUNE RESPONSE MODIFIER FORMULATIONS AND PROCEDURES
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
CL2009001747A1 (es) Composicion farmaceutica que comprende 0,05-0,3% de peroxido de hidrogeno, 0,001-0,03% de eugenol, 0,001-0,01% de alcanfor, 0,001-0,5% de una sal de zinc u otros metales pesados definidos, 1-1,2% de fluoruro de sodio, 2-7% de xilitol y excipientes; metodo de preparacion; uso para prevenir y/o tratar enfermedades orales.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
MX2010007665A (es) Tratamiento de dismenorrea via administracion transdermal de farmacos anti-inflamatorios no esteroideos.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180919